STOCK TITAN
  1. Home
  2. Sec-filings
  3. APLS
  4. [Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity

Apellis (APLS) insider David Watson sells 5,000 shares at $20.06

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Apellis Pharmaceuticals, Inc. (APLS) reported an insider transaction by its General Counsel, David Watson. On 11/17/2025, he sold 5,000 shares of common stock at a price of $20.06 per share in a transaction coded as a sale. The filing states this was a scheduled sale under a Rule 10b5-1 trading plan dated March 3, 2025.

After this transaction, David Watson beneficially owns 108,730 shares of Apellis common stock directly. He also reports indirect ownership of 10,000 shares through a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, over which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Watson David O.
Role General Counsel
Sold 5,000 shs ($100K)
Type Security Shares Price Value
Sale Common Stock 5,000 $20.06 $100K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 108,730 shares (Direct); Common Stock — 10,000 shares (Indirect, Indirect Owner (Custodial Account for minor children))
Footnotes (1)
  1. This was a scheduled sale from 10B5-1 trading plan dated March 3, 2025. This represents a custodial account held by the reporting person for the sole benefit of his minor children. The securities are held by The David O. Watson Irrevocable Trust of 2023. William Zorn is the trustee of The David O. Watson Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The David O. Watson Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Watson David O.
(Last) (First) (Middle)
C/O APELLIS PHARMACEUTICALS, INC
100 FIFTH AVENUE, 3RD FLOOR
(Street)
WALTHAM MA 02451
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/17/2025 S(1) 5,000 D $20.06 108,730 D
Common Stock 10,000 I(2) Indirect Owner (Custodial Account for minor children)
Common Stock 50,136 I(3) Indirect Owner (The David O. Watson Irrevocable Trust of 2023)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This was a scheduled sale from 10B5-1 trading plan dated March 3, 2025.
2. This represents a custodial account held by the reporting person for the sole benefit of his minor children.
3. The securities are held by The David O. Watson Irrevocable Trust of 2023. William Zorn is the trustee of The David O. Watson Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The David O. Watson Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
David Watson 11/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Apellis Pharmaceuticals (APLS) report for David Watson?

The company reported that its General Counsel, David Watson, sold 5,000 shares of Apellis Pharmaceuticals common stock on 11/17/2025 in a transaction coded as a sale.

At what price were the Apellis (APLS) shares sold in David Watson's Form 4?

David Watson sold 5,000 shares of Apellis common stock at a price of $20.06 per share on 11/17/2025.

Was David Watson's sale of Apellis (APLS) stock under a Rule 10b5-1 plan?

Yes. The filing explains that the 5,000-share sale on 11/17/2025 was a scheduled sale made pursuant to a Rule 10b5-1 trading plan dated March 3, 2025.

How many Apellis (APLS) shares does David Watson own after the reported sale?

After the sale, David Watson beneficially owns 108,730 shares of Apellis common stock directly, plus 10,000 shares indirectly via a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023.

What indirect holdings of Apellis (APLS) stock are reported for David Watson?

He reports 10,000 shares held in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, over which he disclaims beneficial ownership except for his pecuniary interest.

What is David Watson's role at Apellis Pharmaceuticals (APLS) in this Form 4?

David Watson is identified as an officer of Apellis Pharmaceuticals, Inc., serving as General Counsel.